Sun J.,University of Macau |
Sun J.,National Institute for Food and Drug Control |
Bi C.,University of Macau |
Chan H.M.,University of Macau |
And 3 more authors.
Colloids and Surfaces B: Biointerfaces | Year: 2013
Purpose: The aim of the present study was to blend liquid lipids with solid lipids to encapsulate curcumin in solid lipid nanoparticles (SLNs), thereby improving the dispersibility and chemical stability of curcumin, prolonging its antitumour activity and cellular uptake and enhancing its bioavailability. Methods: Curcumin-loaded SLNs (C-SLNs) were prepared by high-pressure homogenisation with liquid lipid Sefsol-218®. The morphology, stability and release of curcumin in the optimised formulation were investigated. The anti-cancer activity of the formulation was evaluated in MCF-7 cells. Fluorescence spectrophotometry was used to quantify cellular uptake of the drug. The pharmacokinetic profiles of curcumin in SLNs after intravenous administration were studied in rats. Results: Blending Sefsol-218® into a lipid matrix reduced the particle size without improving drug loading. An optimised formulation consisting of Dynasan 114®, Sefsol-218®, and Pluronic F68® (630:70:300, w/w) loaded with 0.8% drug was prepared. This formulation could be dispersed in water with a mean particle size of 152.8±4.7nm and a 90% entrapment efficiency. Curcumin displayed a two-phase sustained release profile from C-SLNs with improved chemical stability. Compared to the solubilised solution, C-SLNs exhibited prolonged inhibitory activity in cancer cells, as well as time-dependent increases in intracellular uptake. After intravenous administration to rats, the bioavailability of curcumin was increased by 1.25-fold. Conclusions: C-SLNs with improved dispersibility and chemical stability in an aqueous system have been successfully developed. C-SLNs may represent a potentially useful cancer therapeutic curcumin delivery system. © 2013 Elsevier B.V.
News Article | November 2, 2016
GAITHERSBURG, MD - November 2, 2016 - The Institute for In Vitro Sciences (IIVS) welcomes the news from China Food and Drug Administration (CFDA) officials that - for the first time in China - data from a non-animal test method will soon be recognized for safety evaluations of cosmetics. The method, known as the 3T3 Phototoxicity assay, measures a chemical's potential to cause harm after exposure to light. The test has undergone formal validation internationally and has been incorporated into the OECD Test Guideline program (OECD TG #432). A subsequent inter-laboratory evaluation of the test was conducted in China with input from IIVS. Once the method is officially published by CFDA, it can be used to substantiate the safety of cosmetics, personal care products, and their ingredients. "The anticipated publication by CFDA is an extremely important step for China" says Erin Hill, Co-Founder and President of IIVS. "It clearly demonstrates China's commitment to modernize their testing requirements and reduce their reliance on animal models". IIVS and CFDA/National Institute for Food and Drug Control (NIFDC), which has regulatory authority over cosmetics in China, have been working together for several years under a Memorandum of Understanding (MOU) for scientific exchange around the use of non-animal (in vitro) methods for safety assessments. A key component of the MOU is an annual hands-on training provided by IIVS to national and provincial Institute for Food and Drug Control scientists. Over the past four years, approximately 400 regulatory scientists have been trained in methods such as phototoxicity, skin and eye irritation and skin sensitization. IIVS, together with NIFDC, is currently holding its 4th annual training at the laboratory facility of the Zhejiang Institute for Food and Drug control in Hangzhou, China. IIVS Educational and Outreach programs are made possible by funding provided by its Industry Council for the Advancement of Regulatory Acceptance of Alternatives (ICARAA), other individual companies and animal protection organizations such as PETA. About IIVS IIVS is a non-profit organization wholly dedicated to the promotion of rapid and innovative non-animal test methods Founded in 1997, IIVS is recognized as a leading provider of in vitro testing in support of toxicological safety evaluations. Rigorous scientific programs coupled with educational and outreach initiatives have established IIVS as a global leader in the advancement of alternatives to animal testing. For more information, visit http://www. .
Li J.,National Institute for Food and Drug Control |
Liang C.-G.,National Institute for Food and Drug Control
Chinese Journal of New Drugs | Year: 2014
PEGylated rhGH is a kind of modified pharmaceuticals designed by coupling PEG with rhGH to lengthen in vivo half-lives. The introduction of PEG makes the complex more complicated than rhGH in physical and chemical characteristics, and in vivo and in vitro activities. In this article, we analyzed two difficult key points of quality control, namely the average extent of modification and PEGylation sites. Meanwhile, what should be concerned in establishing the specification was also mentioned in this article.
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: Preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial
Zhu F.-C.,U.S. Center for Disease Control and Prevention |
Hou L.-H.,Beijing Institute of Biotechnology |
Li J.-X.,U.S. Center for Disease Control and Prevention |
Wu S.-P.,Beijing Institute of Biotechnology |
And 16 more authors.
The Lancet | Year: 2015
Background Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic strain. Methods We did this randomised, double-blind, placebo-controlled, phase 1 clinical trial at one site in Taizhou County, Jiangsu Province, China. Healthy adults (aged 18-60 years) were sequentially enrolled and randomly assigned (2:1), by computer-generated block randomisation (block size of six), to receive placebo, low-dose adenovirus type-5 vector-based Ebola vaccine, or high-dose vaccine. Randomisation was pre-stratified by dose group. All participants, investigators, and laboratory staff were masked to treatment allocation. The primary safety endpoint was occurrence of solicited adverse reactions within 7 days of vaccination. The primary immunogenicity endpoints were glycoprotein-specific antibody titres and T-cell responses at day 28 after the vaccination. Analysis was by intention to treat. The study is registered with ClinicalTrials.gov, number NCT02326194. Findings Between Dec 28, 2014, and Jan 9, 2015, 120 participants were enrolled and randomly assigned to receive placebo (n=40), low-dose vaccine (n=40), or high-dose vaccine. Participants were followed up for 28 days. Overall, 82 (68%) participants reported at least one solicited adverse reaction within 7 days of vaccination (n=19 in the placebo group vs n=27 in the low-dose group vs n=36 in the high-dose group; p=0·0002). The most common reaction was mild pain at the injection site, which was reported in eight (20%) participants in the placebo group, 14 (35%) participants in the low-dose group, and 29 (73%) participants in the high-dose vaccine group (p<0·0001). We recorded no statistical differences in other adverse reactions and laboratory tests across groups. Glycoprotein-specific antibody titres were significantly increased in participants in the low-dose and high-dose vaccine groups at both day 14 (geometric mean titre 421·4 [95% CI 249·7-711·3] and 820·5 [598·9-1124·0], respectively; p<0·0001) and day 28 (682·7 [424·3-1098·5] and 1305·7 [970·1-1757·2], respectively; p<0·0001). T-cell responses peaked at day 14 at a median of 465·0 spot-forming cells (IQR 180·0-1202·5) in participants in the low-dose group and 765·0 cells (400·0-1460·0) in those in the high-dose group. 21 (18%) participants had mild fever (n=9 in the placebo group, n=6 in the low-dose group, and n=6 in the high-dose group). No serious adverse events were recorded. Interpretation Our findings show that the high-dose vaccine is safe and robustly immunogenic. One shot of the high-dose vaccine could mount glycoprotein-specific humoral and T-cell response against Ebola virus in 14 days. Funding China National Science and Technology, Beijing Institute of Biotechnology, and Tianjin CanSino Biotechnology. © 2015 Elsevier Ltd.
Li L.,CAS Suzhou Institute of Nano Technology and Nano Bionics |
Sun J.,CAS Suzhou Institute of Nano Technology and Nano Bionics |
Li X.,CAS Suzhou Institute of Nano Technology and Nano Bionics |
Zhang Y.,CAS Suzhou Institute of Nano Technology and Nano Bionics |
And 4 more authors.
Biomaterials | Year: 2012
Silver nanoparticles (Ag NPs) are appealing due to their excellent antibacterial/antivirus properties. At the meantime, the wide applications of Ag NPs as antibacterial/antivirus agents arise the concern of Ag NPs' toxicity. However, quantitative understanding of the cytotoxicity of Ag NPs is minimum since that the Ag NPs in current studies have wide size distributions, in which the size effect of Ag NPs on cytotoxicity was unable to be accurately evaluated. In this work, unprecedentedly monodispersed Ag NPs with sizes of 25, 35, 45, 60 and 70 nm were obtained, respectively, by using an optimized polyol method with poly(vinyl pyrrolidone) (PVP) as surfactant. It was found that the reaction temperature, reaction time, concentration of the surfactant and reactants are playing important roles in determining the size and size distribution of Ag NPs. With the monodispersed Ag NPs as standard samples, the size- and dose- dependent cytotoxicity of Ag NPs against Human lung fibroblast (HLF) cells was accurately accomplished in terms of cell viability, apoptosis and necrosis, reactive oxygen species, etc. We expect that the monodispersed Ag NPs will act as the standard samples for quantitatively characterizing the toxicity of Ag NPs in vitro and in vivo. © 2011 Elsevier Ltd.
Shen S.,National Institute for Food and Drug Control |
Shen S.,China National Institute for Nutrition and Food Safety |
Yao J.,National Institute for Food and Drug Control |
Shi Y.,National Institute for Food and Drug Control
Journal of Pharmaceutical and Biomedical Analysis | Year: 2014
This study assessed a general method of quantitative nuclear magnetic resonance (qNMR) for the calibration of atropine sulfate (Active Pharmaceutical Ingredient, API) as reference standard. The spectra were acquired in D2O using maleic acid as the internal standard. Conformational behaviors of tropane ring were observed and studied by means of NMR and ROESY experiments at different temperature, which showed that the azine methyl group was at equilibrium for axial and equatorial conformations at room temperature. Signal delay and monitor signals of qNMR experimentation were optimized for quantification. The study reported here validated the method's linearity, range, limit of quantification, stability and precision. The results were consistent with the results obtained from mass balance approach. © 2013 Elsevier B.V.
Zhang X.,National Institute for Food and Drug Control
Zhongguo yi liao qi xie za zhi = Chinese journal of medical instrumentation | Year: 2014
The paper introduces supervision situation of enterprises of medical devices from the aspects of supervision team of medical devices, construction of credit system and implementation of regulation of quality management of medical devices, and raises supervision difficulties and puts forwards corresponding proposals.
Li J.-X.,Chongqing Medical University |
Li J.-X.,U.S. Center for Disease Control and Prevention |
Mao Q.-Y.,National Institute for Food and Drug Control |
Liang Z.-L.,National Institute for Food and Drug Control |
And 2 more authors.
Expert Review of Vaccines | Year: 2014
The widespread epidemics of enterovirus 71 (EV71) seriously affected the Western Pacific Region. Young children, especially those younger than 3 years are the most susceptible population to the EV71-associated diseases. Several Asian countries have begun to focus on the research and development of EV71 vaccines. Five inactivated whole-virus EV71 candidate vaccines (three were manufactured in mainland China based on a C4 genotype strain, one in Taiwan based on a B4 genotype strain and one in Singapore based on a B2 genotype strain) have been assessed in clinical trials. Three candidate vaccines developed in mainland China have already completed Phase III clinical trials recently. The tested EV71 vaccine could provide good efficacy, satisfactory safety, and high immunogenicity. Thus, inactivated EV71 vaccines are expected to become the first available vaccines against EV71 in the near future. © 2014 Informa UK, Ltd.
Chen L.,National Institute for Food and Drug Control
Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi | Year: 2013
The rat abdominal wall defect and cecal abrasion model was adopted in this study to investigate the anti-adhesion effect of different formulated sodium hyaluronate membranes. Both injured surfaces of abdominal wall and cecum in experiment groups A, B, and C were covered using the corresponding formulated membrane A (composed of sodium hyaluronate and chitosan), membrane B (sodium hyaluronate), and membrane C (composed of sodium hyaluronate and carboxymethyl chitosan), respectively. And no material was used in the surgical as control group. Seven days after the surgery, the grade and score of abdominal adhesion of rats were evaluated according to Phillips' and Nair's classification methods respectively. Then tissue samples were collected and prepared for histological examination. The rank sum tests of scores of adhesion between groups were carried out. It showed that there was no significant difference of adhesion scores among experimental group A and control group (P > 0.05). But the differences were statistically significant (P < 0.01) among group B or C and control group, which indicated the anti-adhesive effect of B formulation and C formulation sodium hyaluronate membranes. The histological examination showed in group A that there was heavy inflammatory cell invasion and necrosis in the newly formed adhesive fibrous tissue, especially in the zone of remaining membrane A. Normal injury healing process was observed in rat abdominal wall and cecal surface covered using membrane B or C. The A formulation sodium hyaluronate membrane had poor biocompatibility which resulted in no anti-adhesion effect. The prevention of adhesion formation by B formulation and C formulation sodium hyaluronate membranes were confirmed in this experiment and would be worthy of further exploitation.
Zhu F.,U.S. Center for Disease Control and Prevention |
Xu W.,National Institutes for Viral Disease Control and Prevention |
Xia J.,PLA Fourth Military Medical University |
Liang Z.,National Institute for Food and Drug Control |
And 27 more authors.
New England Journal of Medicine | Year: 2014
BACKGROUND: Enterovirus 71 (EV71) is one of the major causative agents of outbreaks of hand, foot, and mouth disease or herpangina worldwide. This phase 3 trial was designed to evaluate the efficacy, safety, and immunogenicity of an EV71 vaccine. METHODS: We conducted a randomized, double-blind, placebo-controlled, multicenter trial in which 10,007 healthy infants and young children (6 to 35 months of age) were randomly assigned in a 1:1 ratio to receive two intramuscular doses of either EV71 vaccine or placebo, 28 days apart. The surveillance period was 12 months. The primary end point was the occurrence of EV71-associated hand, foot, and mouth disease or herpangina. RESULTS: During the 12-month surveillance period, EV71-associated disease was identified in 0.3% of vaccine recipients (13 of 5041 children) and 2.1% of placebo recipients (106 of 5028 children) in the intention-to-treat cohort. The vaccine efficacy against EV71-associated hand, foot, and mouth disease or herpangina was 94.8% (95% confidence interval [CI], 87.2 to 97.9; P<0.001) in this cohort. Vaccine efficacies against EV71-associated hospitalization (0 cases vs. 24 cases) and hand, foot, and mouth disease with neurologic complications (0 cases vs. 8 cases) were both 100% (95% CI, 83.7 to 100 and 42.6 to 100, respectively). Serious adverse events occurred in 111 of 5044 children in the vaccine group (2.2%) and 131 of 5033 children in the placebo group (2.6%). In the immunogenicity subgroup (1291 children), an anti-EV71 immune response was elicited by the two-dose vaccine series in 98.8% of participants at day 56. An anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71-associated hand, foot, and mouth disease or herpangina. CONCLUSIONS: The EV71 vaccine provided protection against EV71-associated hand, foot, and mouth disease or herpangina in infants and young children. Copyright © 2014 Massachusetts Medical Society.